Phase 2 Trial of <scp>PD</scp> ‐1 Inhibitor Sintilimab in Recurrent/Progressive Meningioma
Year: 2025
Type: article
Language: en
Topic: Meningioma and schwannoma management
Authors and affiliations:
raw_author_name: Yali Wang
raw_affiliation_strings: Department of Neuro‐Oncology, Cancer Center Beijing Tiantan Hospital, Capital Medical University  Beijing China
Department of Neuro-Oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
raw_author_name: Can Wang
raw_affiliation_strings: Department of Neuro‐Oncology, Cancer Center Beijing Tiantan Hospital, Capital Medical University  Beijing China
Hepato‐Pancreato‐Biliary Center, School of Clinical Medicine, Beijing Tsinghua Changgung Hospital Tsinghua University  Beijing China
Department of Neuro-Oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Hepato-Pancreato-Biliary Center, School of Clinical Medicine, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing, China
raw_author_name: Shuo Yin
raw_affiliation_strings: Department of Neuro‐Oncology, Cancer Center Beijing Tiantan Hospital, Capital Medical University  Beijing China
Department of Neuro-Oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
raw_author_name: Chunna Yu
raw_affiliation_strings: Beijing Luhe Hospital Capital Medical University  Beijing China
Department of Neuro‐Oncology, Cancer Center Beijing Tiantan Hospital, Capital Medical University  Beijing China
Beijing Luhe Hospital, Capital Medical University, Beijing, China
Department of Neuro-Oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
raw_author_name: Xiaojie Li
raw_affiliation_strings: Department of Neurosurgery Beijing Tiantan Hospital, Capital Medical University  Beijing China
Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
raw_author_name: Xun Kang
raw_affiliation_strings: Department of Neuro‐Oncology, Cancer Center Beijing Tiantan Hospital, Capital Medical University  Beijing China
Department of Neuro-Oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
raw_author_name: Shoubo Yang
raw_affiliation_strings: Department of Neuro‐Oncology, Cancer Center Beijing Tiantan Hospital, Capital Medical University  Beijing China
Department of Neuro-Oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
raw_author_name: Wenting Xie
raw_affiliation_strings: Department of Neuro‐Oncology, Cancer Center Beijing Tiantan Hospital, Capital Medical University  Beijing China
Department of Neuro-Oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
raw_author_name: Yi Lin
raw_affiliation_strings: Department of Neuro‐Oncology, Cancer Center Beijing Tiantan Hospital, Capital Medical University  Beijing China
Department of Neuro-Oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
raw_author_name: Zhen Wu
raw_affiliation_strings: Department of Neurosurgery Beijing Tiantan Hospital, Capital Medical University  Beijing China
Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
raw_author_name: Wenbin Li
raw_affiliation_strings: Department of Neuro‐Oncology, Cancer Center Beijing Tiantan Hospital, Capital Medical University  Beijing China
Department of Neuro-Oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
raw_author_name: Feng Chen
raw_affiliation_strings: Department of Neuro‐Oncology, Cancer Center Beijing Tiantan Hospital, Capital Medical University  Beijing China
Department of Neuro-Oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China